{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T03:27:10Z","timestamp":1777865230401,"version":"3.51.4"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004955","name":"\u00d6sterreichische Forschungsf\u00f6rderungsgesellschaft","doi-asserted-by":"publisher","award":["858017"],"award-info":[{"award-number":["858017"]}],"id":[{"id":"10.13039\/501100004955","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.ejmech.2020.112258","type":"journal-article","created":{"date-parts":[[2020,3,26]],"date-time":"2020-03-26T11:26:41Z","timestamp":1585222001000},"page":"112258","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Identification and development of non-cytotoxic cell death modulators: Impact of sartans and derivatives on PPAR\u03b3 activation and on growth of imatinib-resistant chronic myelogenous leukemia cells"],"prefix":"10.1016","volume":"195","author":[{"given":"Anna M.","family":"Schoepf","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Salcher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petra","family":"Obexer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald","family":"Gust","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2020.112258_bib1","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0140-6736(07)61165-9","article-title":"Chronic myeloid leukaemia","volume":"370","author":"Hehlmann","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2020.112258_bib2","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","article-title":"Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia","volume":"8","author":"Apperley","year":"2007","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejmech.2020.112258_bib3","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1038\/leu.2010.185","article-title":"Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR","volume":"24","author":"Ross","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2020.112258_bib4","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1080\/17460441.2017.1356818","article-title":"Therapeutic targeting of leukemic stem cells in acute myeloid leukemia - the biological background for possible strategies","volume":"12","author":"Bruserud","year":"2017","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.ejmech.2020.112258_bib5","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","article-title":"Primitive, quiescent, philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in\u00a0vitro","volume":"99","author":"Graham","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2020.112258_bib6","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2020.112258_bib7","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ejphar.2018.01.036","article-title":"PPARgamma agonists sensitize PTEN-deficient resistant lung cancer cells to EGFR tyrosine kinase inhibitors by inducing autophagy","volume":"823","author":"To","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2020.112258_bib8","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/2211-5463.12055","article-title":"Angiotensin II type 1 receptor blocker telmisartan induces apoptosis and autophagy in adult T-cell leukemia cells","volume":"6","author":"Kozako","year":"2016","journal-title":"FEBS Open Bio"},{"key":"10.1016\/j.ejmech.2020.112258_bib9","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.3892\/ijo.2017.4177","article-title":"Angiotensin receptor blocker telmisartan inhibits cell proliferation and tumor growth of cholangiocarcinoma through cell cycle arrest","volume":"51","author":"Samukawa","year":"2017","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ejmech.2020.112258_bib10","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/nature15248","article-title":"Erosion of the chronic myeloid leukaemia stem cell pool by PPAR\u03b3 agonists","volume":"525","author":"Prost","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2020.112258_bib11","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/cmdc.200800285","article-title":"Characterization of new PPAR\u03b3 agonists: analysis of telmisartan\u2019s structural components","volume":"4","author":"Goebel","year":"2009","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2020.112258_bib12","doi-asserted-by":"crossref","first-page":"111748","DOI":"10.1016\/j.ejmech.2019.111748","article-title":"Overcoming imatinib resistance in chronic myelogenous leukemia cells using non-cytotoxic cell death modulators","author":"Schoepf","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112258_bib13","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.3892\/or.2017.5977","article-title":"Telmisartan inhibits hepatocellular carcinoma cell proliferation in\u00a0vitro by inducing cell cycle arrest","volume":"38","author":"Oura","year":"2017","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.ejmech.2020.112258_bib14","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.leukres.2008.09.029","article-title":"Induction of apoptosis in leukemic cell lines treated with captopril, trandolapril and losartan: a new role in the treatment of leukaemia for these agents","volume":"33","author":"De la Iglesia Inigo","year":"2009","journal-title":"Leuk. Res."},{"key":"10.1016\/j.ejmech.2020.112258_bib15","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1021\/cb3006243","article-title":"Nonsteroidal bivalent estrogen ligands: an application of the bivalent concept to the estrogen receptor","volume":"8","author":"Shan","year":"2013","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2020.112258_bib16","doi-asserted-by":"crossref","first-page":"4350","DOI":"10.1021\/acs.jmedchem.8b01772","article-title":"5-Aryl-1,3,4-oxadiazol-2-ylthioalkanoic acids: a highly potent new class of inhibitors of rho\/myocardin-related transcription factor (MRTF)\/serum response factor (SRF)-mediated gene transcription as potential antifibrotic agents for scleroderma","volume":"62","author":"Kahl","year":"2019","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112258_bib17","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.1021\/jm100047k","article-title":"Characterization of the pharmacophore properties of novel selective estrogen receptor downregulators (SERDs)","volume":"53","author":"Kieser","year":"2010","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112258_bib18","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1002\/cncr.30490","article-title":"Pioglitazone together with imatinib in chronic myeloid leukemia: a proof of concept study","volume":"123","author":"Rousselot","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.ejmech.2020.112258_bib19","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ccell.2015.09.017","article-title":"PPARgamma: welcoming the new kid on the CML stem cell block","volume":"28","author":"Apsel Winger","year":"2015","journal-title":"Canc. Cell"},{"key":"10.1016\/j.ejmech.2020.112258_bib20","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/cbdd.12737","article-title":"Peroxisome proliferator-activated receptor ligands and their role in chronic myeloid leukemia: therapeutic strategies","volume":"88","author":"Yousefi","year":"2016","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.ejmech.2020.112258_bib21","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1161\/01.HYP.0000123072.34629.57","article-title":"Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity","volume":"43","author":"Benson","year":"2004","journal-title":"Hypertension"},{"key":"10.1016\/j.ejmech.2020.112258_bib22","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","article-title":"Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays","volume":"65","author":"Mosmann","year":"1983","journal-title":"J.\u00a0Immunol. Methods"},{"key":"10.1016\/j.ejmech.2020.112258_bib23","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/leu.2014.156","article-title":"Sustained inhibition of STAT5, but not JAK2, is essential for TKI-induced cell death in chronic myeloid leukemia","volume":"29","author":"Schafranek","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2020.112258_bib24","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1182\/blood-2009-10-248211","article-title":"High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia","volume":"117","author":"Warsch","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2020.112258_bib25","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1158\/1535-7163.MCT-07-0397","article-title":"Doxorubicin activates FOXO3a to induce the expression of multidrug resistance gene ABCB1 (MDR1) in K562 leukemic cells","volume":"7","author":"Hui","year":"2008","journal-title":"Mol. Canc. Therapeut."},{"key":"10.1016\/j.ejmech.2020.112258_bib26","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1016\/S0022-2275(20)32433-0","article-title":"Modulation of rat liver apolipoprotein gene expression and serum lipid levels by tetradecylthioacetic acid (TTA) via PPARalpha activation","volume":"40","author":"Raspe","year":"1999","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.ejmech.2020.112258_bib27","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s12943-017-0661-4","article-title":"C10ORF10\/DEPP-mediated ROS accumulation is a critical modulator of FOXO3-induced autophagy","volume":"16","author":"Salcher","year":"2017","journal-title":"Mol. Canc."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523420302257?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523420302257?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T05:59:18Z","timestamp":1777528758000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523420302257"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":27,"alternative-id":["S0223523420302257"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2020.112258","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification and development of non-cytotoxic cell death modulators: Impact of sartans and derivatives on PPAR\u03b3 activation and on growth of imatinib-resistant chronic myelogenous leukemia cells","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2020.112258","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"112258"}}